Cloud-clone
SKU:PAC615Mu02
Polyclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1)
Polyclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1)
Couldn't load pickup availability
Western blotting: 0.2-2µg/mL;1:250-2500
Immunohistochemistry: 5-20µg/mL;1:25-100
Immunocytochemistry: 5-20µg/mL;1:25-100
Optimal working dilutions must be determined by end user.
Product No.
PAC615Mu02
Organism Species
Mus musculus (Mouse).
Source
Polyclonal antibody preparation
Host
Rabbit
Potency
n/a
Ig Type
IgG
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Label
None
Immunogen
RPC615Mu02-Recombinant Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1)
Buffer Formulation
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Traits
Liquid
Concentration
500µg/mL
Organism Species More
n/a
Applications
WB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies.
UOM
20µl 100µl 200µl 1ml 10ml
SPECIFITY
The antibody is a rabbit polyclonal antibody raised against MCL1. It has been selected for its ability to recognize MCL1 in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.5-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
| Magazine | Citations |
| Cancers | Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia Pubmed: 31718075 |
| ACTA NEUROPATHOLOGICA COMMUNICATIONS | Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma Pubmed: 32410663 |
| Cancers (Basel) | BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581 33540760 |
| Catalog No. | Related products for research use of Mus musculus (Mouse) Organism species | Applications (RESEARCH USE ONLY!) |
| RPC615Mu01 | Recombinant Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPC615Mu02 | Recombinant Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC615Mu01 | Polyclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) | WB; IHC; ICC; IP. |
| PAC615Mu02 | Polyclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) | WB; IHC; ICC; IP. |
| SEC615Mu | ELISA Kit for Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMC615Mu | Magnetic Luminex Assay Kit for Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) ,etc. | Magnetic Luminex Assay for Antigen Detection. |
Share
